|
AEGERA PRESENTATIONS AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON
MOLECULAR TARGETS AND CANCER THERAPEUTIC
MONTREAL. November 7, 2005 — Aegera Therapeutics Inc. will be presenting preliminary results of their first human clinical trial for AEG35156 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications in Philadelphia, being held from November 14 - 18, 2005. The presentation will be made by Dr. Malcolm Ranson, Principal Investigator of the study sponsored by Cancer Research UK, and Director of the Derek Crowther Trials Unit at the Christie Hospital in Manchester (UK), at Poster Session C scheduled on Thursday, November 17. Aegera will also be presenting preclinical pharmacodynamic and pharmacokinetic data on AEG35156 in human cancer models. The presentation will be made at Poster Session A by Dr. Jon Durkin, VP Drug Discovery and Preclinical Development at Aegera, on Tuesday, November 15. In addition to these preclinical and clinical presentations on Aegera’s lead drug AEG35156, Dr. Robert Korneluk, Aegera founder and Director of the Apoptosis Research Centre in Ottawa, Ontario, will be discussing the importance of IAP proteins as cancer targets during Plenary Session 5 on Thursday, November 17.
About AEG35156
AEG35156 is now being studied in Europe, the United States, and Canada in three separate clinical studies. AEG35156 is an inhibitor of the X-linked Inhibitor of Apoptosis Protein (XIAP), a protein that is proprietary to Aegera. XIAP is a pivotal inhibitor of apoptosis induced by both intrinsic and extrinsic death cues, and most cancer cell lines over-express XIAP and high levels of XIAP are strongly correlated with poor prognosis in multiple cancers and leukemias. AEG35156 is a second generation XIAP antisense drug, and was designed to be used in combination with a host of traditional and newly-developed cancer therapies to significantly improve treatment efficacy for multiple cancer types. AEG35156 has demonstrated efficacy in all of the in vivo models we have employed, as a stand-alone therapy and in combination with multiple chemotherapy compounds. The combination of AEG35156 with chemotherapeutic agents such as docetaxel represents a potential breakthrough approach to combating resistant cancers.
About Aegera
Aegera Therapeutics Inc. (“Aegera”) is a clinical stage biotechnology company uniquely focused on developing cancer drugs by controlling apoptosis: inducing apoptosis to kill cancer cells and preventing apoptosis to save neuronal cells injured by chemotherapy. Our lead product, AEG35156, is currently in three separate Phase 1b human clinical trials as a monotherapy and as combination therapy, in solid tumors and leukemia. Our second product, AEG33783, designed to protect nerve cells from multiple chemotherapy insults, is in late preclinical development. For more information, please visit Aegera’s website at www.aegera.com.
FOR 9:00 AM (EST) RELEASE
Contact:
Aegera Therapeutics Inc.
514-288-4091, ext. 225
Catherine So
Manager, Business Development
Email: catherine.so@aegera.com
|
